Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain
Influenza is a viral respiratory disease that causes significant clinical and economic burden globally. Quadrivalent influenza vaccine (QIV) is frequently used to protect people who have a high-risk of developing influenza complications due to comorbidities. QIV offers protection against influenza A (A/H1N1 and H3N2) and B (B/Victoria, and B/Yamagata) strains. The European Medicines Agency has recently approved a cell-based QIV (QIVc) in people aged over 9 years old. QIVc has been shown to be more effective at preventing influenza than traditional egg-based QIV (QIVe). In this study, we use a health economic model adapted to Spain to assess the costs and outcomes associated with using QIVc instead of QIVe in people aged 9-64 at high-risk of complications. Observed vaccine coverage of 32% in the 9-17 age group, 17% in those aged 18-59, and 22% for ages 60-64 was used in the analysis. In total, 2.5 million people were vaccinated in the simulations. Using QIVc instead of QIVe was associated with 16,221fewer symptomatic cases, 4,522 fewer primary care visits, 1,015 fewer emergency room visits and 88 fewer hospitalizations. From a societal perspective, QIVc was more effective and less expensive compared to QIVe, leading to a cost-saving of €3.4 million. From a public payer perspective, the incremental cost-effectiveness ratio for QIVc vs QIVe was €12,852 per QALY gained. In conclusion, QIVc offers a cost-effective alternative to QIVe and should be considered as an alternative vaccine to QIVe for people aged 9-64 at high-risk of influenza complications in Spain.
| Errataetall: |
CommentIn: Hum Vaccin Immunother. 2021 Mar 4;17(3):694-695. - PMID 32961079 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 16(2020), 9 vom: 01. Sept., Seite 2238-2244 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruiz-Aragón, Jesús [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Burden of illness |
|---|
| Anmerkungen: |
Date Completed 21.06.2021 Date Revised 30.03.2024 published: Print-Electronic CommentIn: Hum Vaccin Immunother. 2021 Mar 4;17(3):694-695. - PMID 32961079 Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2020.1712935 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306349078 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306349078 | ||
| 003 | DE-627 | ||
| 005 | 20240330232415.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2020.1712935 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM306349078 | ||
| 035 | |a (NLM)32040379 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruiz-Aragón, Jesús |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2021 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Hum Vaccin Immunother. 2021 Mar 4;17(3):694-695. - PMID 32961079 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Influenza is a viral respiratory disease that causes significant clinical and economic burden globally. Quadrivalent influenza vaccine (QIV) is frequently used to protect people who have a high-risk of developing influenza complications due to comorbidities. QIV offers protection against influenza A (A/H1N1 and H3N2) and B (B/Victoria, and B/Yamagata) strains. The European Medicines Agency has recently approved a cell-based QIV (QIVc) in people aged over 9 years old. QIVc has been shown to be more effective at preventing influenza than traditional egg-based QIV (QIVe). In this study, we use a health economic model adapted to Spain to assess the costs and outcomes associated with using QIVc instead of QIVe in people aged 9-64 at high-risk of complications. Observed vaccine coverage of 32% in the 9-17 age group, 17% in those aged 18-59, and 22% for ages 60-64 was used in the analysis. In total, 2.5 million people were vaccinated in the simulations. Using QIVc instead of QIVe was associated with 16,221fewer symptomatic cases, 4,522 fewer primary care visits, 1,015 fewer emergency room visits and 88 fewer hospitalizations. From a societal perspective, QIVc was more effective and less expensive compared to QIVe, leading to a cost-saving of €3.4 million. From a public payer perspective, the incremental cost-effectiveness ratio for QIVc vs QIVe was €12,852 per QALY gained. In conclusion, QIVc offers a cost-effective alternative to QIVe and should be considered as an alternative vaccine to QIVe for people aged 9-64 at high-risk of influenza complications in Spain | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Influenza | |
| 650 | 4 | |a Quadrivalent influenza vaccine (QIV) | |
| 650 | 4 | |a Spain | |
| 650 | 4 | |a burden of illness | |
| 650 | 4 | |a cell-based vaccines | |
| 650 | 4 | |a cost-effectiveness | |
| 650 | 4 | |a high-risk | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 700 | 1 | |a Gani, Ray |e verfasserin |4 aut | |
| 700 | 1 | |a Márquez, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarez, Piedad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 16(2020), 9 vom: 01. Sept., Seite 2238-2244 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2020 |g number:9 |g day:01 |g month:09 |g pages:2238-2244 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2020.1712935 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2020 |e 9 |b 01 |c 09 |h 2238-2244 | ||